Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction

Journal of Cerebral Blood Flow and Metabolism

Volumn 33, Issue 2, 2013, Pages 287-292

  Prodan, Calin I ^a   Stoner, Julie A ^a   Cowan, Linda D ^a   Dale, George L ^b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

platelets; recurrence; stroke; thrombosis

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CELL SUBPOPULATION; CEREBROVASCULAR ACCIDENT; COATED PLATELET LEVEL; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NONLACUNAR BRAIN INFARCTION; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; THROMBOCYTE;

ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BRAIN INFARCTION; COLLAGEN; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET FUNCTION TESTS; STROKE; THROMBIN;

EID: 84873410847     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2012.168     Document Type: Article

References (32)

1. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemostasis 2005; 3: 2185-2192.
2. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002; 415: 175-179.
3. Dale GL, Remenyi G, Friese P. Quantitation of microparticles released from coated-platelets. J Thromb Haemostasis 2005; 3: 2081-2088.
4. Remenyi G, Szasz R, Friese P, Dale GL. Role of mitochondrial permeability transition pore in coated-platelet formation. Arterioscler Thromb Vasc Biol 2005; 25: 467-471.
5. Alberio L, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen and convulxin. Blood 2000; 95: 1694-1702.
6. Brooks MB, Catalfamo JL, Friese P, Dale GL. Scott syndrome dogs have impaired coated-platelet formation and calcein release but normal mitochondrial depolarization. J Thromb Haemostasis 2007; 5: 1972-1974.
7. Prodan CI, Joseph PM, Vincent AS, Dale GL. Coated-platelet levels are influenced by smoking, aspirin and selective serotonin reuptake inhibitors. J Thromb Hae-mostasis 2007; 5: 2149-2151.
8. Norgard NB, Saya S, Hann CL, Hennebry TA, Schechter E, Dale GL. Clopidogrel attenuates coated-platelet production in patients undergoing elective coronary catheterization. J Cardiovasc Pharmacol 2008; 52: 536-539.
9. Valaydon ZS, Lee P, Dale GL, Januszewski AS, Rowley KG, Nandurkar H et al. Increased coated-platelet levels in chronic haemodialysis patients. Nephrology (Carlton) 2009; 14: 148-154.
10. Prodan CI, Joseph PM, Vincent AS, Dale GL. Coated-platelets in ischemic stroke: differences between lacunar and cortical stroke. J Thromb Haemostasis 2008; 6: 609-614.
11. Prodan CI, Stoner JA, Cowan LD, Dale GL. Lower coated-platelet levels are associated with early hemorrhagic transformation in patients with non-lacunar brain infarction. J Thromb Haemostasis 2010; 8: 1185-1190.
12. Prodan CI, Vincent AS, Padmanabhan R, Dale GL. Coated-platelet levels are low in patients with spontaneous intracerebral hemorrhage. Stroke 2009; 40: 2578-2580.
13. Prodan CI, Vincent AS, Dale GL. Coated platelet levels correlate with bleed volume in patients with spontaneous intracerebral hemorrhage. Stroke 2010; 41: 1301-1303.
14. Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
15. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL. Coated-platelets retain amyloid precursor protein on their surface. Platelets 2006; 17: 56-60.
16. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 2011; 76: 247-252.
17. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005; 36: 916-923.
18. Jenkins AJ, Gosmanova AK, Lyons TJ, May KD, Dashti A, Baker MZ et al. Coated-platelet levels in patients with type 1 and with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 81: e8-10.
19. Petty GW, Brown Jr RD, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000; 31: 1062-1068.
20. Lovett JK, Coull AJ, Rothwell PM. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology 2004; 62: 569-573.
21. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577-617.
22. Coull AJ, Rothwell PM. Underestimation of the early risk of recurrent stroke: evidence of the need for a standard definition. Stroke 2004; 35: 1925-1929.
23. Jackson C, Sudlow C. Comparing risks of death and recurrent vascular events between lacunar and non-lacunar infarction. Brain 2005; 128: 2507-2517.
24. Kellerer AM, Chmelevsky D. Small-sample properties of censored-data rank tests. Biometrics 2012; 39: 675-682.
25. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995; 48: 1503-1510.
26. Hintze J. PASS 2008. NCSS, LLC: Kaysville, Utah, 2008.
27. Biller J. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy. J Neurol Sci 2009; 284: 1-9.
28. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612-1623.
29. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, doubleblind, placebo-controlled trial. Lancet 2004; 364: 331-337.
30. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-1717.
31. Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 2003; 108: 399-406.
32. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011; 377: 1681-1692.